Skip to content

An application study of stellate ganglion block intervention for the recurrence of atrial fibrillation

An application study of stellate ganglion block intervention for the recurrence of atrial fibrillation

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102305
Enrollment
Unknown
Registered
2025-05-13
Start date
2025-05-15
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Group L:Left-sided stellate ganglion block
Group R:Right-sided stellate ganglion block
Group C:None

Sponsors

People's Hospital of Ningxia Hui Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: The subjects selected for this study must meet all the following conditions: 1) Age >= 40 years old and = 2 hours; 7) RFCA is feasible after comprehensive clinical evaluation by cardiologists in the research group; 8) Consent to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Subjects with any of the following conditions cannot be included in this study: 1. Those who refuse to participate in this study. 2. Those with a history of schizophrenia, epilepsy, Parkinson's disease, or depression. 3. Those who are unable to complete the pre-operative assessment due to severe dementia, speech disorders, coma, end-stage diseases, etc. 4. Critically ill patients (patients with an American Society of Anesthesiologists (ASA) preoperative classification of >= Grade IV, see Annex 1); those with severe renal impairment (patients requiring renal replacement therapy); those with severe liver function impairment (Child-Pugh Class C) (see Annex 2). 5. Permanent atrial fibrillation that cannot be electrically cardioverted. 6. Atrial fibrillation associated with valvular disease. 7. Structural heart disease with left ventricular hypertrophy.

Design outcomes

Primary

MeasureTime frame
The recurrence situation of atrial fibrillation in the near and long term after transcatheter radiofrequency ablation.;Plasma norepinephrine and acetylcholine concentrations;

Secondary

MeasureTime frame
Comorbidities before surgery, the type of atrial fibrillation, the method of transcatheter ablation, the use of anti-arrhythmic drugs (AAD) or the situation of taking the drugs again;

Countries

China

Contacts

Public ContactZhouXiaohong

People's Hospital of Ningxia Hui Autonomous Region

1123820991@qq.com+86 138 9519 5370

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026